

## SPECIAL FEATURES

### CCR Pediatric Oncology Series

Complimentary access to this online-only series of articles from the AACR Childhood Cancer Predisposition Workshop:  
[clincancerres.aacrjournals.org/pediatricseries](http://clincancerres.aacrjournals.org/pediatricseries)

- e133** **The Future of Surveillance in the Context of Cancer Predisposition: Through the Murky Looking Glass**  
David Malkin, Kim E. Nichols, Joshua D. Schiffman, Sharon E. Plon, and Garrett M. Brodeur

### Highlights of This Issue 6379

### CCR Translations

- 6381** **Sarcomatoid Renal Cell Carcinoma: The Apple Doesn't Fall Far from the Tree**  
Paulo Bergerot, Neeraj Agarwal, Sumanta K. Pal, and Jeremy Jones  
*See related article, p. 6686*

### CCR Drug Updates

- 6384** **FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen**  
Christy L. Osgood, Meredith K. Chuk, Marc R. Theoret, Lan Huang, Kun He, Leah Her, Patricia Keegan, and Richard Pazdur

### Molecular Pathways

- 6390** **Molecular Pathways: Targeting the Microenvironment of Liver Metastases**  
Simon Milette, Jason K. Sicklick, Andrew M. Lowy, and Pnina Brodt

## CANCER THERAPY: CLINICAL

- 6400** **Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors**  
Mallika S. Dhawan, Imke H. Bartelink, Rahul Raj Aggarwal, Jim Leng, Jenna Z. Zhang, Nela Pawlowska, Manuela Terranova-Barberio, Jennifer A. Grabowsky, Andrew Gewitz, Amy J. Chien, Mark Moasser, Robin K. Kelley, Tayeba Maktabi, Scott Thomas, and Pamela N. Munster

- 6411** **Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies**  
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, Fritz Offner, Dominique Bron, Marie Maerevoet, Jean-Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, Jean-Marie Michot, Karen Silence, Anna Hultberg, Domenica Gandini, Hans de Haard, Vincent Ribrag, Marc Peeters, Alain Thibault, Nicolas Leupin, and Ahmad Awada

- 6421** **Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies**  
Shailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, Jiuping Ji, Jacqueline M. Greer, Richard Piekarz, Judith E. Karp, Keith W. Pratz, and Michelle A. Rudek

- 6430** **Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature**  
Charles F. Craddock, Aimee E. Houlton, Lynn Swun Quek, Paul Ferguson, Emma Gbandi, Corran Roberts, Marlen Metzner, Natalia Garcia-Martin, Alison Kennedy, Angela Hamblin, Manoj Raghavan, Sandeep Nagra, Louise Dudley, Keith Wheatley, Mary Frances McMullin, Srinivas P. Pillai, Richard J. Kelly, Shamyla Siddique, Michael Dennis, Jamie D. Cavenagh, and Paresh Vyas

- 6441** **A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma**  
Sara M. Federico, M. Beth McCarville, Barry L. Shulkin, Paul M. Sondel, Jacquelyn A. Hank, Paul Hutson, Michael Meagher, Aaron Shafer, Catherine Y. Ng, Wing Leung, William E. Janssen, Jianrong Wu, Shenghua Mao, Rachel C. Brennan, Victor M. Santana, Alberto S. Pappo, and Wayne L. Furman

- 6450** **Underreporting of Research Biopsies from Clinical Trials in Oncology**  
Christine M. Parseghian, Kanwal Raghav, Robert A. Wolff, Joe Ensor Jr, James Yao, Lee M. Ellis, Alda L. Tam, and Michael J. Overman



# Table of Contents

## PERSONALIZED MEDICINE AND IMAGING

- 6458** Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment  
Elena Martínez-García, Antoine Lesur, Laura Devis, Silvia Cabrera, Xavier Matias-Guiu, Marc Hirschfeld, Jasmin Asberger, Jan van Oostrum, María de los Ángeles Casares de Cal, Antonio Gómez-Tato, Jaume Reventos, Bruno Domon, Eva Colas, and Antonio Gil-Moreno
- 6468** A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors  
Kurt W. Evans, Erkan Yuca, Argun Akcakanat, Stephen M. Scott, Natalia Paez Arango, Xiaofeng Zheng, Ken Chen, Coya Tapia, Emily Tarco, Agda K. Eterovic, Dalliah M. Black, Jennifer K. Litton, Timothy A. Yap, Debu Tripathy, Gordon B. Mills, and Funda Meric-Bernstam
- 6478** An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia  
Roni Shouval, Annalisa Ruggeri, Myriam Labopin, Mohamad Mohty, Guillermo Sanz, Gerard Michel, Jürgen Kuball, Patrice Chevallier, Amal Al-Seraihy, Noel-Jean Milpied, Cristina Diaz de Heredia, William Arcese, Didier Blaise, Vanderson Rocha, Joshua Fein, Ron Unger, Frederic Baron, Peter Bader, Eliane Gluckman, and Arnon Nagler
- 6487** Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer  
Gillian Vandekerckhove, Tilman Todenhöfer, Matti Annala, Werner J. Struss, Amanda Wong, Kevin Beja, Elie Ritch, Sonal Brahmbhatt, Stanislav V. Volik, Jörg Hennenlotter, Matti Nykter, Kim N. Chi, Scott North, Arnulf Stenzl, Colin C. Collins, Bernhard J. Eigel, Peter C. Black, and Alexander W. Wyatt
- 6498** <sup>89</sup>Zr-anti-γH2AX-TAT but not <sup>18</sup>F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma  
James C. Knight, Michael J. Mosley, Luisa Contreras Bravo, Veerle Kersemans, P. Danny Allen, Somnath Mukherjee, Eric O'Neill, and Bart Cornelissen

- 6505** Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER<sup>+</sup>/HER2<sup>-</sup> Breast Cancer  
Bas H.M. van der Velden, Sjoerd G. Elias, Tycho Bismeyer, Claudette E. Loo, Max A. Viergever, Lodewyk F.A. Wessels, and Kenneth G.A. Gilhuijs

## CANCER THERAPY: PRECLINICAL

- 6516** Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer  
Jin Liu, Mikael Agopiantz, Joël Poupon, Zherui Wu, Pierre-Alexandre Just, Bruno Borghese, Evelyne Ségal-Bendirdjian, Guillaume Gauchotte, Anne Gompel, and Patricia Forgez
- 6529** Targeting RNA-Polymerase I in Both Chemosensitive and Chemosistant Populations in Epithelial Ovarian Cancer  
Robert Cornelison, Zachary C. Dobbin, Ashwini A. Katre, Dae Hoon Jeong, Yinfeng Zhang, Dongquan Chen, Yuliya Petrova, Danielle C. Llana, Adam D. Steg, Laura Parsons, David A. Schneider, and Charles N. Landen
- 6541** Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation  
Noriaki Tanaka, Ameeta A. Patel, Lin Tang, Natalie L. Silver, Antje Lindemann, Hideaki Takahashi, Roman Jaksik, Xiayu Rao, Nene N. Kalu, Tseng-Cheng Chen, Jiping Wang, Mitchell J. Frederick, Faye Johnson, Frederico O. Gleber-Netto, Siqing Fu, Marek Kimmel, Jing Wang, Walter N. Hittelman, Curtis R. Pickering, Jeffrey N. Myers, and Abdullah A. Osman
- 6555** *In Vivo* Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target  
Ada W.Y. Leung, Chansey J. Veinotte, Nicole Melong, Min Hee Oh, Kent Chen, Katey S.S. Enfield, Ian Backstrom, Corinna Warburton, Donald Yapp, Jason N. Berman, Marcel B. Bally, and William W. Lockwood
- 6567** Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation  
Puyu Shi, You-Take Oh, Liang Deng, Guojing Zhang, Guoqing Qian, Shuo Zhang, Hui Ren, Grant Wu, Benjamin Legendre, JrEmily Anderson, Suresh S. Ramalingam, Taofeek K. Owonikoko, Mingwei Chen, and Shi-Yong Sun

# Table of Contents

**6580** The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer  
Shu-Xiong Zeng, Yanjun Zhu, Ai-Hong Ma, Weimin Yu, Hongyong Zhang, Tzu-Yin Lin, Wei Shi, Clifford G. Tepper, Paul T. Henderson, Susan Airhart, Jian-Ming Guo, Chuan-Liang Xu, Ralph W. deVere White, and Chong-Xian Pan

**6592** Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer  
Max Kates, Abhijit Date, Takahiro Yoshida, Umara Afzal, Pranjali Kanvinde, Taarika Babu, Nikolai A. Sopko, Hotaka Matsui, Noah M. Hahn, David J. McConkey, Alexander Baras, Justin Hanes, Laura Ensign, and Trinity J. Bivalacqua

**6602** Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma  
Elizabetha A. Rojas, Luis Antonio Corchete, Laura San-Segundo, Juan F. Martínez-Blanch, Francisco M. Codoñer, Teresa Paño, Noemí Puig, Ramón García-Sanz, María Victoria Mateos, Enrique M. Ocio, Irena Misiewicz-Krzeminska, and Norma C. Gutiérrez

**6616** <sup>131</sup>I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment  
Matthias D'Huyvetter, Jens De Vos, Catarina Xavier, Marek Pruszynski, Yann G.J. Sterckx, Sam Massa, Geert Raes, Vicky Caveliers, Michael R. Zalutsky, Tony Lahoutte, and Nick Devoogdt

## BIOLOGY OF HUMAN TUMORS

**6629** p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy  
Myrthala Moreno-Smith, Anna Lakoma, Zaowen Chen, Ling Tao, Kathleen A. Scorsone, Linda Schild, Kevin Aviles-Padilla, Rana Nikzad, Yankai Zhang, Rikhia Chakraborty, Jan J. Molenaar, Sanjeev A. Vasudevan, Vivien Sheehan, Eugene S. Kim, Silke Paust, Jason M. Shohet, and Eveline Barbieri

**6640** Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/ $\beta$ -Catenin Signaling  
Guangzhi Wang, Jia Shen, Jiahang Sun, Zhenfeng Jiang, Jiabing Fan, Hongjun Wang, Shan Yu, Yu Long, Yi Liu, Hongbo Bao, Kelvin Xi Zhang, Ke Han, Minwei Zhu, Yongri Zheng, Zhiguo Lin, Chuanlu Jiang, and Mian Guo

**6650** Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival  
Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, Matthew Genet, Galina Gritsina, Balázs Gyórfy, Priscilla K. Brastianos, David C. Binder, Jeffrey A. Sosman, Francis J. Giles, Charles D. James, Craig Horbinski, Roger Stupp, and Derek A. Wainwright

**6661** Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring *MET* Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I *MET* Inhibitors in Nonclinical Models  
Lars D. Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A. Tovar, Curt J. Essenburg, Zachary Madaj, Harrah Chiang, David Briere, Jill Hallin, Pedro P. Lopez-Casas, Natalia Baños, Camino Menendez, Manuel Hidalgo, Vanessa Tassell, Richard Chao, Darya I. Chudova, Richard B. Lanman, Peter Olson, Lyudmilla Bazhenova, Sandip Pravin Patel, Carrie Graveel, Mizuki Nishino, Geoffrey I. Shapiro, Nir Peled, Mark M. Awad, Pasi A. Jänne, and James G. Christensen

**6673** The KMT1A-GATA3-STAT3 Circuit Is a Novel Self-Renewal Signaling of Human Bladder Cancer Stem Cells  
Zhao Yang, Luyun He, Kaisu Lin, Yun Zhang, Aihua Deng, Yong Liang, Chong Li, and Tingyi Wen

**6686** Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape  
Zixing Wang, Tae Beom Kim, Bo Peng, Jose Karam, Chad Creighton, Aron Joon, Fumi Kawakami, Patricia Trevisan, Eric Jonasch, Chi-Wan Chow, Jaime Rodriguez Canales, Pheroze Tamboli, Nizar Tannir, Christopher Wood, Federico Monzon, Keith Baggerly, Marileila Varela-Garcia, Bogdan Czerniak, Ignacio Wistuba, Gordon Mills, Kenna Shaw, Ken Chen, and Kanishka Sircar  
*See related commentary, p. 6381*

**6697** Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner  
Anna Kreutzman, Beatriz Colom-Fernández, Ana Marcos Jiménez, Mette Ilander, Carlos Cuesta-Mateos, Yaiza Pérez-García, Cristina Delgado Arévalo, Oscar Brück, Henna Hakonen, Jani Saarela, Alvaro Ortega-Carrión, Ana de Rosendo, Alba Juanes-García, Juan Luis Steegmann, Satu Mustjoki, Miguel Vicente-Manzanares, and Cecilia Muñoz-Calleja



# Table of Contents

**6708** Diverse *BRCA1* and *BRCA2* Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, Lei Tian, Jane L. Meisel, Isaac García-Murillas, Charlotte Fribbens, Ros Cutts, Luciano G. Martelotto, Charlotte K.Y. Ng, Raymond S. Lim, Pier Selenica, Salvatore Piscuoglio, Carol Aghajanian, Larry Norton, Rajmohan Murali, David M. Hyman, Laetitia Borsu, Maria E. Arcila, Jason Konner, Jorge S. Reis-Filho, Roger A. Greenberg, Mark E. Robson, and Nicholas C. Turner

**6721** Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and *MUTYH*-associated Polyposis

Laura E. Thomas, Joanna J. Hurley, Elena Meuser, Sian Jose, Kevin E. Ashelford, Matthew Mort, Shelley Idziaszczyk, Julie Maynard, Helena Leon Brito, Manon Harry, Angharad Walters, Meera Raja, Sarah-Jane Walton, Sunil Dolwani, Geraint T. Williams, Meleri Morgan, Morgan Moorghen, Susan K. Clark, and Julian R. Sampson

**6733** Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance

Amber E. Bannon, Jason Kent, Isaac Forquer, Ajia Town, Lillian R. Klug, Kelly McCann, Carol Beadling, Oliver Harismendy, Jason K. Sicklick, Christopher Corless, Ujwal Shinde, and Michael C. Heinrich

**6744** *Numb*<sup>-/low</sup> Enriches a Castration-Resistant Prostate Cancer Cell Subpopulation Associated with Enhanced Notch and Hedgehog Signaling


Yanjing Guo, Kai Zhang, Chaping Cheng, Zhongzhong Ji, Xue Wang, Minglei Wang, Mingliang Chu, Dean G. Tang, Helen He Zhu, and Wei-Qiang Gao

 AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows a section of low-grade serous ovarian carcinoma. Inhibition of neurotensin receptor 1 in ovarian cancer is correlated with higher carboplatin response. For details, see the article by Liu and colleagues on page 6516 of this issue.



# Clinical Cancer Research

**23 (21)**

*Clin Cancer Res* 2017;23:e133-6756.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/23/21>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/21>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.